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A 49-year-old man was referred to our endocrine unit in 2012 with a 15-year history of 42 
widespread incapacitating bone and joint pain, which was now causing marked insomnia. 43 
Physical examination revealed proximal muscle weakness, waddling gait, kyphosis and a right 44 
metacarpal swelling. Previous biochemical investigations had revealed a low serum 25-OH 45 
vitamin D of 16 ng/mL [reference range (RR) 30-100], elevated serum alkaline phosphatase (391 46 
U/L; RR 53-128), normal serum corrected calcium (9 mg/dL; RR 8.5-10.5) and a low serum 47 
phosphorous level (1.8 mg/dL; RR 2.5-5). He had previously undergone extensive radiological 48 
and rheumatological investigations, which were ‘inconclusive’. Plain X-ray studies had revealed 49 
multiple rib and vertebral fractures. MRI of the spine showed diffuse sclerosis of the vertebral 50 
column and pelvic bones. A Tc-99m-MDP bone scan performed in the year 2000 had shown 51 
increased uptake over the ribs bilaterally (Fig.1A), which was initially reported as suspicious for 52 
metastases. However, extensive cross-sectional imaging with CT and MRI failed to identify an 53 
underlying primary lesion. Prior to the current presentation he was treated with multiple 54 
analgesics, calcium, phosphorous and calcitriol preparations. However, none of these resulted in 55 
any improvement in his symptoms. 56 
 57 
As there were no other systemic/localizing features, we considered the possibility of a primary 58 
metabolic bone disorder. A repeat phosphorus level was persistently low (1.86 mg/dL), with an 59 
inappropriate 24-hour urinary phosphorus of 745 mg/day (RR <1000) and the % Tubular 60 
Reabsorption of Phosphate (% TRP) off supplements was 0.68 (RR>0.8). 25-OH vitamin D (32 61 
ng/mL) and parathyroid hormone levels (49 pg/mL; RR 14-72) were normal, but 1,25-(OH)2 62 
vitamin D was inappropriately low (3.5 pg/ml; RR 19.6-54.3). In view of this, plasma C-terminal 63 
Fibroblast growth factor 23 (FGF-23) level was measured (Immutopics, USA), which was grossly 64 
elevated at 3088 RU/mL (RR 0-150). A whole body 18F-FDG-PET scan showed focal tracer 65 
uptake on the radial and dorsal aspect of the head of the right second metacarpal (SUVmax=2·5) 66 
(Fig.1B, C, D). Histological analyses of the surgically-resected metacarpal lesion revealed a 67 
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phosphaturic mesenchymal cell tumor (PMT), mixed connective tissue variant with negative 68 
FGF-23 and somatostatin receptor subtype (SSTR) 2A immunostaining (Fig.1E, F, G). Despite 69 
the latter, FGF-23 levels declined rapidly to 246 RU/mL on day 6 postoperatively, with 70 
progressive symptom relief, confirming a diagnosis of tumor-induced osteomalacia (TIO).  71 
 72 
In view of persisting (albeit considerably improved) pain and mild hypophosphataemia (2.4 73 
mg/dL), a repeat 18F-FDG-PET scan was performed in 2013 and showed low-grade residual 74 
uptake over the head of the right second metacarpal. After careful discussion with the patient, a 75 
ray amputation of the index finger was performed with histology confirming complete excision of 76 
the residual tumor. Following the second operation, FGF-23 levels dropped to 152 RU/mL, but 77 
the hypophosphataemia persisted. His pain improved although he described on-going mild 78 
symptoms. Several months later the patient reported an increase in the intensity of his bone pain. 79 
He had persistent hypophosphataemia with rising FGF-23 levels (224.5 RU/mL). In 2015, a 80 
whole body 68Ga-DOTANOC-PET scan was performed, which revealed no uptake at the site of 81 
the previous surgery. However, a left nasal cavity lesion (2.9 x 2.0 cm), (Fig.1H, I) with avid 82 
tracer uptake (SUVmax 3.79) was seen. Retrospectively, this lesion could be seen on the 18F-83 
FDG-PET, although at that time the relatively low level of tracer uptake was not felt to be 84 
significant. However, axial reconstruction clearly shows the lesion (Fig. 1J). Further review of the 85 
more historical imaging suggested that this was also probably visible on the original Tc-99m-86 
MDP bone scan (Supplementary Fig.A, B). Transnasal endoscopic resection of the nasal lesion 87 
revealed a predominant, phosphaturic mesenchymal cell tumor (Fig.1K, L) with negative FGF-23 88 
immunostaining but positive SSTR 2A immunostaining (Fig.1M), suggestive of a multifocal TIO. 89 
Post-operatively FGF-23 levels returned to normal within 48 hours of surgery (64.6 RU/mL), and 90 
currently remain within the reference range (50.3 RU/mL) at 3 months, with normalization of 91 
phosphorous levels (4.2 mg/dL) and, for the first time, complete resolution of his symptoms.  92 
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Tumors that secrete phosphaturic factors/phosphatonins (e.g. FGF-23) are usually benign and the 93 
predominant cause of TIO or oncogenic osteomalacia. As in our patient, the resulting 94 
hypophosphataemia can cause debilitating pain. Complete resection of a unifocal tumor typically 95 
leads to full resolution of symptoms. However, localization of these tumors is often difficult due 96 
to their small size and diverse locations (limb extremities to the head, including soft tissues, 97 
bones, sinuses, brain). Systematic physical examination, combined with cross-sectional and 98 
functional imaging is essential for localization. Amongst functional scans, some studies have 99 
shown somatostatin receptor ligand based imaging [e.g. 111Indium-Octreotide SPECT, (1) 99Tc-100 
HYNIC-TOC SPECT(2) and Gallium based 68Ga-DOTA-TATE PET(2-5)] to be better for  101 
identifying PMT in comparison to other imaging modalities such as 18F-FDG-PET. In a large case 102 
series, Chong et al showed that amongst 19 pathologically confirmed TIO subjects, 18 were 103 
octreo-SPECT scan positive [sensitivity 0.95, specificity 0.64, positive predictive value (PPV) of 104 
0.82 and a negative predictive value (NPV) of 0.88] and 14 out of 16 confirmed TIO subjects 105 
were FDG-PET positive (sensitivity 0.88, specificity 0.36, PPV of 0.62 and NPV of 0.50). In 106 
addition, in a small number of subjects 68Ga-DOTA-TATE/DOTANOC PET has localised TIOs 107 
that were not previously identified with 18F-FDG-PET (2) and 111Indium-Octreotide SPECT 108 
imaging (3). In our case the intense brain uptake of 18F-FDG-PET obscured the lesion in the nasal 109 
cavity (Fig.1B), and it was only on retrospective review of axial imaging that the lesion was noted 110 
(Fig.1J).  111 
 112 
Occasionally, even with the best efforts to localize these tumors, they may remain elusive (‘a 113 
needle in the haystack’). In this scenario, a combined imaging approach with structural and 114 
nuclear imaging affords the best opportunity for localization. Moreover, in the setting of multiple 115 
suspicious lesions on initial imaging, or with a possible multi-focal TIO similar to our case, an 116 
ideal initial approach retrospectively could have included biopsy of both the lesions and/or 117 
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selective venous sampling of FGF-23 around the sites of the lesions. Selective venous sampling 118 
has been shown to help in tumor localization by using an FGF-23 venous concentration ratio 119 
between the venous drainage of the tumor bed in comparison to the general circulation (6). In this 120 
way, selective venous sampling can differentiate between a culprit lesion and other incidental 121 
lesions thereby avoiding unnecessary surgery (6).  122 
 123 
Previous reports have always noted complete normalization of hypophosphataemia and FGF-23 124 
levels with successful surgery. In our case, biochemical normalization did not happen in spite of 125 
complete surgical excision of the metacarpal lesion following second surgery. Although 126 
multifocality is extremely rare, and has only previously been described in four patients (7-10), 127 
persisting symptoms and failure of FGF-23 levels to normalize after complete excision of the 128 
metacarpal lesion prompted a detailed re-evaluation of the case, and the adoption of more 129 
sensitive imaging in the form of Ga-68 DOTANOC PET. It is likely that if the latter had been 130 
used as the preferred imaging modality at the time of his referral to our service, then a structured 131 
approach as outlined above, combining selective venous sampling and biopsy would potentially 132 
have led to earlier identification of the multifocality, although still have required two separate 133 
surgical procedures. 134 
 135 
This image highlights the importance of a multimodal, perseverant approach towards the 136 
investigation and treatment of patients with persistent unexplained hypophosphataemia and 137 
chronic bone pain, and serves as an important reminder of possible multifocal disease in 138 
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Figure legend  180 
 181 
(A) Tc-99m-MDP Bone scan showing increased tracer uptake at multiple sites; (B) Whole body 182 
18F-FDG-PET scan revealing FDG avid soft tissue thickening over the radial and dorsal aspect of 183 
the head of the right second metacarpal (SUVmax=2.5); Fused 18F-FDG-PET & CT of the right 184 
hand in (C) sagittal and (D) coronal planes; (E) Histological examination of metacarpal lesion 185 
showing diffuse proliferation of bland tumor cells in a patternless arrangement around vessels (F) 186 
with bluish smudgy matrix; (G) Vimentin positivity on immunohistochemistry (IHC); (H) Whole 187 
body Ga-68-DOTANOC-PET scan showing avid tracer uptake within left nasal cavity lesion (2.9 188 
x 2.0 cms, SUVmax 3.9); (I) Fused Ga-68 DOTANOC PET & CT scan head; (J) 18F-FDG-PET 189 
SPECT CT Head axial imaging demonstrates the left nasal cavity lesion with a low SUV uptake 190 
(SUV Max = 2.1); (K) Histological examination of nasal lesion showing bland tumor cells with 191 
fibromyxoid stroma, heamangiopericytomatous pattern of vasculature [arrow], (L) smudgy matrix 192 
[arrow]; (M) IHC shows strong positive staining for somatostatin receptor subtype 2 A 193 
(SSTR2A); (N) Graph depicting the trends in FGF-23 levels over time.  194 
Figure – Annamalai et al
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